List of figures (European Drug Report 2026)
This page contains a full list of all figures and graphical elements available in the European Drug Report 2026. Please note that, if viewing this page as part of a PDF, the links will direct you to the online versions, not the corresponding figures in the PDF. The links are organised below according to the chapter in which they appear.
This page is part of the European Drug Report 2026, the EUDA's annual overview of the drug situation in Europe.
Last update: 9 June 2026
List of figures by chapter
- Understanding Europe’s drug situation in 2026 – key developments
- Drug supply, production and precursors
- Figure 1.1. Examples of drug trafficking methods previously reported by law enforcement in Europe
- Figure 1.2. Cocaine seizures at sea
- Figure 1.3. Synthetic cathinone production facility with 185 kilograms of 4-CMC (clephedrone) seized, Pyskowice, Poland, 2024
- Figure 1.4. Drug seizures in the European Union – quantity of drugs seized, indexed trends (2014 = 100)
- Figure 1.5. Drug seizures in the European Union – number of reported drug seizures, breakdown by drug, 2024 (percent)
- Figure 1.6. Drug seizures in the European Union
- Figure 1.7. Drug seizures in the European Union – number of drug seizures, indexed trends (2014 = 100)
- Figure 1.8. Drug law offences – number of offences, supply and use/possession, 2024
- Figure 1.9. Drug law offences – possession/use offences, indexed trends (2014 = 100)
- Figure 1.10. Drug law offences – supply offences, indexed trends (2014 = 100)
- Figure 1.11. Quantities of precursors (EU) and key non-scheduled chemicals seized in the European Union
- Figure 1.12. Illicit methadone production sites dismantled in Poland, August 2024
- Cannabis – the current situation in Europe
- Figure 2.1. Drones (left) and a speedboat (right) used in cannabis trafficking seized in Spain in 2025
- Figure 2.2. Small- and large-scale illicit cannabis cultivation sites dismantled in Ireland (left) and Spain (right)
- Figure 2.3. Prevalence of cannabis use in Europe
- Figure 2.4. Cannabis residues in wastewater in selected European cities: changes between 2024 and 2025
- Figure 2.5. People entering treatment for cannabis in Europe
- Figure 2.6a. Cannabis resin market in Europe
- Figure 2.6b. Herbal cannabis market in Europe
- Cocaine – the current situation in Europe
- Figure 3.1. Seizures of cocaine trafficked by sea and air
- Figure 3.2. Large cocaine production site dismantled in Spain, 2024
- Figure 3.3. Prevalence of cocaine use in Europe
- Figure 3.4. Cocaine residues in wastewater in selected European cities: changes between 2024 and 2025
- Figure 3.5. Clients entering treatment for cocaine use
- Figure 3.6. Trends in the numbers of cocaine-related presentations in Euro-DEN Plus sentinel hospitals, 2023 to 2024
- Figure 3.7. Polysubstance toxicity in drug-induced death cases with cocaine involved, 2024 (or most recent year available)
- Figure 3.8. Cocaine market in Europe
- Synthetic stimulants – the current situation in Europe
- Figure 4.1. Seizures of amphetamine in Sweden (left two) and methamphetamine in Germany (right two), 2025
- Figure 4.2. Synthetic cathinones seized at a laboratory in Poland, 2024
- Figure 4.3. Large synthetic cathinone laboratory dismantled in Latvia, 2024
- Figure 4.4. Prevalence of amphetamines use in Europe
- Figure 4.5. Amphetamine residues in wastewater in selected European cities: changes between 2024 and 2025
- Figure 4.6. Methamphetamine residues in wastewater in selected European cities: changes between 2024 and 2025
- Figure 4.7. Clients entering treatment for amphetamine use in Europe
- Figure 4.8. Clients entering treatment for methamphetamine use in Europe
- Figure 4.9. Clients entering treatment for synthetic cathinones in Europe
- Figure 4.10. Amphetamine market in Europe
- Figure 4.11. Methamphetamine market in Europe
- MDMA – the current situation in Europe
- Figure 5.1. MDMA production facility dismantled by Belgian Police in 2024
- Figure 5.2. Example of risk alert communications issued at two music festivals in Ireland, 2025
- Figure 5.3. Purity of MDMA powder samples submitted to drug checking services in 2024 and 2025
- Figure 5.4. Content of MDMA tablet samples submitted to drug checking services in 2024 and 2025
- Figure 5.5. Prevalence of MDMA ('ecstasy') use in Europe
- Figure 5.6. MDMA residues in wastewater in selected European cities: changes between 2024 and 2025
- Figure 5.7. MDMA market in Europe
- Figure 5.8. Adulterants detected in samples sold as MDMA tablets or powder and tested in 14 European drug checking services in 2025
- Heroin and other opioids – the current situation in Europe
- Figure 6.1. Age distribution of all clients entering treatment with heroin as their primary drug, 2014 and 2024
- Figure 6.2. Age distribution of never previously treated clients entering treatment with heroin as their primary drug, 2014 and 2024
- Figure 6.3. Trends in the main route of administration of clients entering treatment with heroin as primary drug, by treatment status
- Figure 6.4. Lage seizures of concealed heroin concealed in cable machines and mattress, Bulgaria, 2024
- Figure 6.5. Users entering treatment for heroin in Europe
- Figure 6.6a. Proportion of acute drug toxicity presentations with mention of heroin in Euro-DEN Plus hospitals, 2024
- Figure 6.6b. Trends in the proportion of presentations with mention of heroin in 2016-2024, in selected Euro-DEN Plus hospitals
- Figure 6.7. Heroin market in Europe
- New psychoactive substances – the current situation in Europe
- Figure 7.1. Seized warehouse and laboratory producing synthetic cannabinoids in Greece, 2023
- Figure 7.2. Products containing the synthetic cannabinoids MDMB-PINACA and MDMB-4en-PINACA linked to poisonings in Czechia, September 2025
- Figure 7.3. Semi-synthetic cannabinoids production facility dismantled in 2023 by Romanian police
- Figure 7.4. Part of a seizure of 185 kilograms of synthetic cathinones seized at a dismantled synthetic drug production laboratory in Pyskowice, Poland, 2024
- Figure 7.5. Fake oxycodone tablets containing metonitazene, seized in Sweden in 2023
- Figure 7.6. Cychlorphine mis-sold online as a benzodiazepine pro-drug (alprazolam triazolobenzophenone pellets), Germany, September 2025
- Figure 7.7. Number of new psychoactive substances reported for the first time to the EU Early Warning System, by category, 2005-2025
- Figure 7.8. Number of new psychoactive substances reported each year following their first identification in the European Union, by category, 2005-2025
- Figure 7.9. Number of new opioids reported for the first time to the EU Early Warning System, 2009-2025
- Figure 7.10. Seizures of new psychoactive substances in the European Union, 2006-2024
- Figure 7.11. Seizures of new psychoactive substances in the European Union: percentage of total quantity seized, by substance, 2024
- Other drugs – the current situation in Europe
- Figure 8.1. Number of formal notifications of benzodiazepines reported to the EU Early Warning System, 2005-2025
- Figure 8.2. Illicit benzodiazepine tablets seized in Ireland
- Figure 8.3. Ketamine residues in wastewater in selected European cities: changes between 2024 and 2025
- Figure 8.4. Proportion of acute drug toxicity presentations with mention of GHB/GBL, Euro-DEN Plus sentinel hospitals, 2024
- Figure 8.5. Seizures of ketamine powder in the European Union: total quantity (kilograms), 2006-2024
- Figure 8.6. Seizures of ketamine powder in the European Union: total number, 2006-2024
- Injecting drug use in Europe – the current situation
- Figure 9.1. Estimated prevalence of people who inject drugs in the last 12 months (per 1000 population), 2024 or latest data
- Figure 9.2. Estimated number of people who inject drugs in the last 12 months, by country, 2024 or latest data
- Figure 9.3. Trends in injecting among first-time treatment entrants with heroin, cocaine, amphetamine or methamphetamine as primary drug: percentage reporting injecting as main route of administration
- Figure 9.4. Percentage of used syringes tested positive by drug category, by city, 2024
- Drug-related infectious diseases – the current situation in Europe
- Figure 10.1. New HIV notifications linked to injecting drug use in the European Union, 2009 to 2024
- Figure 10.2. Number of sterile syringes distributed per person who injects drugs per year, 2024 or latest data
- Figure 10.3. Most-recent documented HIV outbreaks in EUDA member states among people who inject drugs: number of HIV cases and the associated injected substance, 2014 to 2024
- Figure 10.4. Trends in HCV-RNA prevalence (%) among people who inject drugs: results from seroprevalence studies, 2013-2024
- Drug-induced deaths – the current situation in Europe
- Figure 11.1. Opioids mentioned in drug-induced deaths, by substance, 2024
- Figure 11.2. Proportion of males among drug-induced deaths in the European Union, Norway and Türkiye in 2024, or most recent year (percent)
- Figure 11.3. Number and rates per million population of drug-induced deaths reported in the European Union in 2014 and 2024, or the most recent year, by sex and age band
- Figure 11.4a. Drug-induced deaths in the European Union
- Figure 11.4b. Drug-induced deaths in the European Union: age at death, 2024 or most recent available data (percent)
- Figure 11.4c. Trends in drug-induced deaths in the European Union, Norway and Türkiye
- Figure 11.4d. Age distribution (percent) of drug-induced deaths reported in the European Union, Norway and Türkiye in 2024 or the most recent year
- Figure 11.5. Proportion of drug-induced deaths with opioids mentioned, 2024 or most recent available data
- Opioid agonist treatment – the current situation in Europe
- Harm reduction – the current situation in Europe
- Figure 13.1 Common sterile harm reduction supplies for high-risk drug use
- Figure 13.2. Number of European countries implementing selected harm reduction interventions, up to 2024
- Figure 13.3. Interventions to prevent opioid-related deaths, by intended aim and evidence of benefit
- Figure 13.4. A rapid risk communication issued in Netherlands, 2025
- Figure 13.5. Needle and syringe distribution and opioid agonist treatment coverage in relation to WHO 2025 targets, 2024 or latest available estimate
- Figure 13.6. Availability of take-home naloxone, available formulations, number of persons trained and number of kits given out, in Europe
- Figure 13.7. An illustration of the range of drug checking technologies available and their relative accuracy and reliability
- Figure 13.8. Location and number of drug consumption facilities throughout Europe, 2025
- Figure 13.9. Availability of drug-related and other health and social care interventions targeting people who use drugs and are in prison, Europe, 2024 Number of countries where the intervention was officially available in 2024